State of Alaska Department of Revenue Purchases New Holdings in Arcutis Biotherapeutics, Inc. $ARQT

Posted by Brian Himes on Oct 24th, 2026

State of Alaska Department of Revenue purchased a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,772 shares of the company’s stock, valued at approximately $653,000.

Several other hedge funds also recently modified their holdings of ARQT. Montanova Capital LLC grew its stake in shares of Arcutis Biotherapeutics by 0.9% in the second quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock worth $326,098,000 after acquiring an additional 110,000 shares during the last quarter. BlackRock Inc. acquired a new position in Arcutis Biotherapeutics during the 2nd quarter valued at $276,502,000. Bank of America Corp DE acquired a new position in Arcutis Biotherapeutics during the 2nd quarter valued at $78,330,000. Janus Henderson Group PLC raised its stake in Arcutis Biotherapeutics by 1.3% during the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock valued at $43,684,000 after purchasing an additional 24,505 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new position in Arcutis Biotherapeutics during the 2nd quarter valued at $36,989,000.

Arcutis Biotherapeutics Stock Performance

ARQT opened at $31.20 on Friday. The stock’s 50 day simple moving average is $26.04 and its 200-day simple moving average is $25.12. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 0.46. The stock has a market cap of $3.92 billion, a PE ratio of 153.33 and a beta of 1.57. Arcutis Biotherapeutics, Inc. has a 1 year low of $19.30 and a 1 year high of $33.30.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. The firm had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. Sell-side analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Guggenheim increased their price target on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a “buy” rating in a report on Monday. Needham & Company LLC boosted their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings lowered shares of Arcutis Biotherapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 14th. Wall Street Zen lowered shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Finally, Cantor Fitzgerald initiated coverage on shares of Arcutis Biotherapeutics in a research note on Thursday, October 15th. They issued an “overweight” rating and a $48.00 target price for the company. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Read Our Latest Report on ARQT

Insider Transactions at Arcutis Biotherapeutics

In other news, insider Patrick Burnett sold 6,700 shares of Arcutis Biotherapeutics stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $26.08, for a total transaction of $174,736.00. Following the sale, the insider directly owned 119,289 shares in the company, valued at approximately $3,111,057.12. The trade was a 5.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Masaru Matsuda sold 3,674 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $91,850.00. Following the completion of the sale, the insider directly owned 112,508 shares in the company, valued at approximately $2,812,700. The trade was a 3.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 83,953 shares of company stock worth $2,143,291. 9.40% of the stock is currently owned by company insiders.

About Arcutis Biotherapeutics

(Free Report)

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.